C.D. PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
C.D. PHARMA
Largest movements
- Tangible fixed assets -€6,380
down €6,380 (-7.0%), from €91,510 to €85,130
- Profit (loss) carried forward -€10,408
down €10,408 (-15.3%), from -€68,185 to -€78,593
- Other debts +€3,996
up €3,996 (+1.7%), from €241,327 to €245,323
- Gross operating margin -€181
down €181 (-13.3%), from -€1,358 to -€1,539
- Other operating charges +€72
up €72 (+3.0%), from €2,385 to €2,457
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Cash or the result is not a separate line in both sets of accounts; the cash flow cannot be derived from them.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €277,041 | €270,629 | -€6,412 | -2.3% |
| Fixed assets | 21/28 | €276,527 | €270,147 | -€6,380 | -2.3% |
| Tangible fixed assets | 22/27 | €91,510 | €85,130 | -€6,380 | -7.0% |
| Land and buildings | 22 | €91,510 | €85,130 | -€6,380 | -7.0% |
| Financial fixed assets | 28 | €185,017 | €185,017 | = | 0.0% |
| Current assets | 29/58 | €514 | €482 | -€32 | -6.2% |
| Current investments | 50/53 | €514 | €482 | -€32 | -6.2% |
| Total equity and liabilities | 10/49 | €277,041 | €270,629 | -€6,412 | -2.3% |
| Equity | 10/15 | €35,714 | €25,306 | -€10,408 | -29.1% |
| Contributions | 10/11 | €6,205 | €6,205 | = | 0.0% |
| Reserves | 13 | €97,694 | €97,694 | = | 0.0% |
| Non-distributable reserves | 130/1 | €1,860 | €1,860 | = | 0.0% |
| Reserves not available under the articles | 1311 | €1,860 | €1,860 | = | 0.0% |
| Distributable reserves | 133 | €95,834 | €95,834 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€68,185 | -€78,593 | -€10,408 | -15.3% |
| Amounts payable | 17/49 | €241,327 | €245,323 | +€3,996 | +1.7% |
| Amounts payable within one year | 42/48 | €241,327 | €245,323 | +€3,996 | +1.7% |
| Other amounts payable | 47/48 | €241,327 | €245,323 | +€3,996 | +1.7% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €6,381 | €6,381 | = | 0.0% |
| Other operating charges | 640/8 | €2,385 | €2,457 | +€72 | +3.0% |
| Gross operating margin | 9900 | -€1,358 | -€1,539 | -€181 | -13.3% |
| Operating profit (loss) | 9901 | -€10,124 | -€10,377 | -€253 | -2.5% |
| Financial charges | 65/66B | €34 | €31 | -€3 | -8.8% |
| Recurring financial charges | 65 | €34 | €31 | -€3 | -8.8% |
| Profit (loss) for the period before taxes | 9903 | -€10,158 | -€10,408 | -€250 | -2.5% |
| Profit (loss) for the period | 9904 | -€10,158 | -€10,408 | -€250 | -2.5% |
| Profit (loss) for the period to be appropriated | 9905 | -€10,158 | -€10,408 | -€250 | -2.5% |
Source: filed annual accounts (NBB), financial years ended 30 November 2024 and 30 November 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 10 October 2026 via checked.be.